Asthma Sample Clauses

Asthma. The following services related to asthma are covered with $0 Out-of-Pocket Cost when linked to a primary diagnosis of asthma and performed by a Network Provider: • Office visits to a Primary Care Provider for routine management of asthma • Office visits to a Pulmonologist (lung specialist) for consultation and routine management of asthma • Office visits to an Allergist (allergy specialist) for consultation and routine management of asthma • Palliative care conversations (chronic condition treatment preferences) with Primary Care Provider, Pulmonologist, or Allergist • Immunotherapy for allergen sensitization to reduce impact and severity of allergic reactions • Inhaler adjuncts (e.g., spacer) as specified on the formulary and dispensed through our Home Delivery Program • Pulmonary function tests • Asthma education [allergens/triggers, asthma action plan and behavioral modification counseling] • Targeted laboratory tests for the routine management of asthma Please note, if you have complications from asthma and use an urgent care center, emergency department, or have a Hospital stay, services will be subject to standard Out-of-Pocket Costs as outlined in your Schedule of Benefits.
Sample 1Sample 2See All (5)
AutoNDA by SimpleDocs
Asthma. Asthma is a chronic, incurable disease which causes many symptoms that make breathing difficult [3]. Around 5% of the Medicare population in the Parkview area is affected by asthma, as well a portion of the population of adults and children. Asthma as a chief health concern was not mentioned in the community or provider surveys, but asthma in the Medicare population appeared as a primary concern in several of the seven counties according to HCI. While the population affected may be small, the disease burden is high due to expensive and potentially life-long costs associated with managing symptoms of asthma. There are several clinical intervention strategies recommended by healthcare professionals to reduce the frequency and severity of symptoms. Table 5: Asthma Xxxxx Xxxxxxxxxx Kosciusko LaGrange Noble Wabash Xxxxxxx Asthma 5.6% 6% 4.5% 3.6% 5.5% 4.8% 5.5% *In Medicare population
Sample 1Sample 2Sample 3
Asthma. Since phthalates are well-known endocrine disruptors, a large amount of research focuses on effects on the reproductive system, the thyroid and metabolism (Huang, Kuo, Guo, Liao, & Xxx, 2007; Lyche et al., 2009). We are interested in its influence on respiratory system. Asthma, characterized by recurrent bronchial hyperresponsiveness, is one of most common pulmonary diseases in the Xxxxxx Xxxxxx. Xx 0000-0000, asthma prevalence was 8.8% among adults. Overall asthma prevalence among adults increased from 2001-2002 (7.1%) to 2013-2014 (9.2%) (CDC). Common clinical symptoms of asthma include coughing, wheezing, shortness of breath and chest tightness. Symptoms are typically exacerbated at night and in the early morning or related to exercise or inspiration of cold air in winter. Airway inflammation, airflow obstruction, and irreversible airway remodeling are believed to be involved in asthma development. The respiratory system of a human contains two lungs, the trachea, the bronchi in the mediastinum, and the bronchial trees (bronchi branches). The trachea and its large proximal branches form a passageway for air exchange between the lung and the external environment (Gilroy, 2013). Asthma primarily targets at the bronchi and its subdivisions and conducting bronchioles. The pathogenesis of asthma can be classified into two categories. One is intrinsic asthma mainly caused by viral infection (e.g., rhinovirus, parainfluenza virus, respiratory syncytial virus), air pollutants, aspirin or other nonsteroidal medication use (Goljan, 2013). The other one is extrinsic asthma which involves a classical inflammation process. Mast cells, IgE antibodies, leukotrienes, chemokines and cytokines participate in the inflammation process and lead to histologic changes, such as thickening of the basement membranes, infiltration of inflammatory cells, hypertrophy of mucous glands, hypertrophy of smooth muscle cells and hyperplasia (Kumar, Abbas, & Aster, 2012). Narrowing of the bronchi causes expiratory wheezing in asthma, and the air trapping in distal bronchioles leads to the increased anteroposterior thoracic diameter, especially in long-term untreated asthma patients. Although the mechanisms have not yet been elucidated, there are several encouraging laboratory research findings pertaining to the cellular mechanisms through which phthalates may influence inflammation and allergic response. For example, the production of pro-inflammatory chemokines and cytokines in human mac...
Sample 1
Asthma. Implement targeted education and outreach activities to increase awareness of and disseminate resources on childhood asthma management, including management before, during and after a disaster. Grantee will:
Sample 1
Asthma 
Sample 1

Related to Asthma

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • MEDICALLY FRAGILE STUDENTS 1. If a teacher will be providing instructional or other services to a medically fragile student, the teacher or another adult who will be present when the instruction or other services are being provided will be advised of the steps to be taken in the event an emergency arises relating to the student's medical condition.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Screening 3.13.1 Refuse containers located outside the building shall be fully screened from adjacent properties and from streets by means of opaque fencing or masonry walls with suitable landscaping.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to FDA or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and for studies submitted to regulatory authorities for approval, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Service Animals Humber Residence acknowledges the rights of persons with disabilities to retain their service animal while living in Residence. In order to preserve the health and safety of all people and animals living or working in the Residence environment, the Resident will notify the Residence Office that they require a service animal and will provide documentation as outlined in the Accessibility for Ontarians with Disabilities Act confirming that the Resident requires the service animal. The Resident will also complete a Service Animal Agreement with the Residence Manager or designate, and agrees to adhere to the requirements within it.

  • Medication 1. Xxxxxxx’s physician shall prescribe and monitor adequate dosage levels for each Client.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.